Literature DB >> 30084367

Immunotherapy: hype and hope.

.   

Abstract

Mesh：

Year:  2018        PMID： 30084367     DOI： 10.1016/S1470-2045(18)30317-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

1.  Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations.

Authors:  Josep Tabernero
Journal:  ESMO Open       Date:  2019-01-31

2.  The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis.

Authors:  Huilin Xu; Ximing Xu; Wei Ge; Jinju Lei; Dedong Cao
Journal:  Ther Adv Med Oncol       Date:  2020-12-18       Impact factor: 8.168

3.  Is There Already a Need of Reckoning on Cancer Immunotherapy?

Authors:  Pierpaolo Correale; Francesca Pentimalli; Giovanni Baglio; Marjia Krstic-Demonacos; Rita Emilena Saladino; Antonio Giordano; Luciano Mutti
Journal:  Front Pharmacol       Date:  2021-03-26       Impact factor: 5.810

4.  Sodium-glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway.

Authors:  Xiaoping Zhan; Lijun Cheng; Ning Huo; Lin Yu; Changle Liu; Tong Liu; Guangping Li; Huaying Fu
Journal:  Front Cardiovasc Med       Date:  2022-09-06

5.  Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review.

Authors:  Houssein Safa; Monica Tamil; Philippe E Spiess; Brandon Manley; Julio Pow-Sang; Scott M Gilbert; Firas Safa; Brian D Gonzalez; Laura B Oswald; Adele Semaan; Adi Diab; Jad Chahoud
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

6.  Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs.

Authors:  Alyson Haslam; Vinay Prasad
Journal:  JAMA Netw Open       Date:  2019-05-03

7.  NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells.

Authors:  Vincenzo Quagliariello; Michelino De Laurentiis; Stefania Cocco; Giuseppina Rea; Annamaria Bonelli; Antonietta Caronna; Maria Cristina Lombari; Gabriele Conforti; Massimiliano Berretta; Gerardo Botti; Nicola Maurea
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.